Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study

Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study

Introduction: The availability of targeted therapies has transformed the management of advanced NSCLC; however, most patients do not undergo guideline-recommended tumor genotyping. The impact of plasma-based next-generation sequencing (NGS) performed simultaneously with diagnostic biopsy in suspecte...

Full description

Bibliographic Details
Main Authors: Jeffrey C. Thompson, MD, MTR, Charu Aggarwal, MD, MPH, Janeline Wong, BS, Vivek Nimgaonkar, BS, Wei-Ting Hwang, PhD, Michelle Andronov, BS, David M. Dibardino, MD, Christoph T. Hutchinson, MD, MA, Kevin C. Ma, MD, Anthony Lanfranco, MD, MS, Edmund Moon, MD, Andrew R. Haas, MD, PhD, Aditi P. Singh, MD, Christine A. Ciunci, MD, MSCE, Melina Marmarelis, MD, MSCE, Christopher D’Avella, MD, Justine V. Cohen, DO, Joshua M. Bauml, MD, Roger B. Cohen, MD, Corey J. Langer, MD, Anil Vachani, MD, MSCE, Erica L. Carpenter, MBA, PhD
Format: Article
Language:English
Published: Elsevier 2022-04-01
Series:JTO Clinical and Research Reports
Subjects:
Lung cancer
Precision medicine
Lung cancer genomics
Circulating tumor DNA
Multidisciplinary
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432200025X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432200025X

Similar Items